Role of terlipressin in the treatment of infants and neonates with catecholamine-resistant septic shock.

Abstract

The present paper is aimed at reviewing new findings on the use of terlipressin in children with septic shock. The level of evidence based on the data available in the literature is very low. Three series of cases and four isolated cases report on the use of terlipressin in children with catecholamine-refractory septic shock. The aggregated population represents 39 children. The dosages of boli vary from 7 microg/kg twice a day to 2 microg/kg every 4 hours. Low-dose continuous infusion has also been described. Terlipressin injection is associated with an approximately 30% increase in blood pressure. Mortality of these children with catecholamine refractory septic shock is 54%. The paucity of most reports does not make it possible to conclude on the global and microcirculatory effects of this treatment. Future studies are required before any recommendations on the use of terlipressin in children with septic shock can be made.

• Authors: Marc Leone, Claude Martin
• Journal: Best practice & research. Clinical anaesthesiology (Best Pract Res Clin Anaesthesiol) Vol. 22 Issue 2 Pg. 323-33 (Jun 2008) ISSN: 1521-6896 [Print] Netherlands
• PMID: 18683478 (Publication Type: Journal Article, Review)

Chemical References

• Catecholamines
• Vasoconstrictor Agents
• Vasopressins
• Lypressin
• Terlipressin

Topics

• Animals
• Catecholamines (therapeutic use)
• Drug Resistance
• Humans
• Infant
• Infant, Newborn
• Lypressin (analogs & derivatives, therapeutic use)
• Shock, Septic (drug therapy)
• Terlipressin
• Vasoconstrictor Agents (therapeutic use)
• Vasopressins (blood, physiology, therapeutic use)